Loading...
Loading...
ME| Name | Value |
|---|---|
| Revenues | 50.0M |
| Cost of Revenue | 28.3M |
| Gross Profit | 21.7M |
| Operating Expense | 98.2M |
| Operating I/L | -79.1M |
| Other Income/Expense | 3.9M |
| Interest Income | 3.8M |
| Pretax | -75.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -75.3M |
23andMe Holding Co. operates as a consumer genetics testing company, offering genetic reports on ancestral origins, health risks, and carrier conditions. Its saliva-based genetic testing kit provides insights into medication responses. The company also focuses on drug development and therapies for oncology, respiratory, and cardiovascular diseases. Additionally, it engages in out-licensing of intellectual property related to drug targets. Through a collaboration with GlaxoSmithKline, it validates, develops, and commercializes drugs based on genetic insights. The company generates revenue through consumer genetic testing services and drug development activities.
